AbCellera Biologics Inc.

Based in Vancouver, British Columbia, AbCellera Biologics is a publicly traded biotechnology company that discovers and develops antibody-based therapeutics targeting indications with limited treatment options. The company's pipeline centers on monoclonal antibodies designed to address unmet medical needs across multiple therapeutic areas. Its lead candidate, ABCL635, is in Phase 2 clinical development for moderate-to-severe vasomotor symptoms, while ABCL575, a fully human monoclonal antibody with extended half-life properties, is in Phase 1 testing for T-cell-mediated autoimmune conditions including atopic dermatitis.

AbCellera operates through research collaborations and licensing agreements with established pharmaceutical partners. The company maintains strategic relationships with Eli Lilly and Company, AbbVie Inc., and Biogen Inc., as well as partnerships with investment firms Viking Global Investors and ArrowMark Partners. These collaborations support both clinical development and potential commercialization of its antibody candidates.

The company was incorporated in 2012 and operates with a market capitalization of approximately $1.1 billion as of the most recent reporting period. AbCellera's business model relies on advancing its proprietary antibody pipeline through clinical trials while leveraging partnerships to share development costs and expand market access.